November 25, 2024
The Maryland Prescription Drug Affordability Board invites you to attend the November Board Meeting, scheduled for Monday, November 25, 2024 at 2:00 pm. Part of the meeting may be conducted in closed session. Because the meeting will be livestreamed here, registration is not required. You may also attend in person at the following address:
Miller Senate Building, William Amoss Room, 4th Floor
11 Bladen Street
Annapolis, MD 21401
PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email comments.pdab@maryland.gov no later than the close of business on Wednesday, November 20, 2024, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation and provide additional details.
WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to comments.pdab@maryland.gov. Please include in the subject line: November Board Meeting Comments. Please submit any written comments concerning this agenda no later than the close of business on Wednesday, November 20, 2024.
AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.
October 28, 2024- Ad-Hoc MeetingThe Maryland Prescription Drug Affordability Board invites you to attend the October Board Meeting, scheduled for Monday, October 28, 2024 at 2:00 pm. The meeting will be held remotely. Part of the meeting may be conducted in closed session. Please register for the meeting here. After registering, you will receive a confirmation email with information about joining the webinar. PDAB staff politely requests that you mute your line after entering the meeting.
PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email comments.pdab@maryland.gov no later than the close of business on Wednesday, October 23, 2024, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.
WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to comments.pdab@maryland.gov. Please submit any written comments, concerning this agenda no later than the close of business on Monday, Wednesday, October 23, 2024. Please utilize the subject line “October Board Comments.”
AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.
- Comments Received for the 10/28/2024 Meeting
September 10, 2024The Maryland Prescription Drug Affordability Board invites you to attend the September Board Meeting, scheduled for Tuesday, September 10, 2024 at 2:00 pm. The meeting will be held remotely. Part of the meeting may be conducted in closed session. Please register for the meeting here. After registering, you will receive a confirmation email with information about joining the webinar. PDAB staff politely requests that you mute your line after entering the meeting.
Please note that the September 23, 2024 scheduled PDAB meeting has been CANCELED and rescheduled for September 10, 2024.
PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email comments.pdab@maryland.gov no later than the close of business on Thursday, September 5, 2024, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.
WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to comments.pdab@maryland.gov. Please submit any written comments, concerning this agenda no later than the close of business on Monday, Thursday, September 5, 2024. Please utilize the subject line “Sept Board Comments.”
AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.
July 22, 2024
The Maryland Prescription Drug Affordability Board invites you to attend the July Board Meeting, scheduled for Monday, July 22, 2024, at 2:00 pm. Part of the meeting may be conducted in closed session. Because the meeting will be livestreamed
here, registration is not required. You may also attend in person at the following address:
Miller Senate Building, William Amoss Room, 4th Floor
11 Bladen Street
Annapolis, MD 21401
PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email comments.pdab@maryland.gov no later than the close of business on Wednesday, July 17, 2024, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation and provide additional details.
WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to comments.pdab@maryland.gov. Please include in the subject line: July Board Meeting Comments. Please submit any written comments concerning this agenda no later than the close of business on Wednesday, July 17, 2024.
AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.
Comments Received for the July 22nd Meeting: The following entities provided written comment in the above packet: - MedChi
- Manva Singla, M.D., F.A.A.P., F.A.A.A.A.I., F.A.C.A.A.A.I., Allergy Asthma Specialists of Maryland
- PhRMA
- Boehringer Ingelheim
- Johnson and Johnson
May 20, 2024
The Maryland Prescription Drug Affordability Board invites you to attend the May Board Meeting, scheduled for Monday, May 20, 2024, at 2:00 pm. Part of the meeting may be conducted in closed session. Because the meeting will be livestreamed
here, registration is not required. You may also attend in person at the following address:
Miller Senate Building, William Amoss Room, 4th Floor
11 Bladen Street
Annapolis, MD 21401
PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email comments.pdab@maryland.gov no later than the close of business on Wednesday, May 15, 2024, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation and provide additional details.
WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to comments.pdab@maryland.gov. Please include in the subject line: May Board Meeting Comments. Please submit any written comments concerning this agenda no later than the close of business on Wednesday, May 15, 2024.
AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.
Comments Received for May 20th Board Meeting:
The following entities provided written comment in the above packet:
Melissa Lynn Abrams, MD, FAAD
American Partnership for Eosinophilic Disorders
Oluyomi Amoye- Consumer (Verifying this is ok to post)
AstraZeneca
Baltimore-Washington Conference of the United Methodist Church
Committee to Protect Health Care
Delaware-Maryland Synod
Amit Mickey Dhir, MSN, MBA, AGPCNP-C, AAHIVS
Families USA- The Voice for Healthcare Consumers
Gilead
HIV+HEP Policy Institute
Infectious Disease Care Center
Susan Lovelace, MS, CRNP
Partnership to Improve Patient Care
Progressive Maryland
Regeneron
Value of Care Coalition
Dr. Chikoti Wheat
Brittany Yerkes, MS PA-C, AAHIVM
Comments Received for May 20th Board Meeting after deadline and not included in the packet above:
March 25, 2024
The Maryland Prescription Drug Affordability Board invites you to attend the March Board Meeting, scheduled for Monday, March 25, 2024, at 2:00 pm, remotely. Part of the meeting may be conducted in closed session. Please register for the meeting here. After registering, you will receive a confirmation email with information about joining the webinar. PDAB staff politely requests that you mute your line after entering the meeting
PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email comments.pdab@maryland.gov no later than the close of business on Wednesday, March 20, 2024, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail
WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to comments.pdab@maryland.gov. Please submit any written comments concerning this agenda no later than the close of business on Wednesday, March 20, 2024.
AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.
-
Written Public Comment - The following entities provided written comment in the above attachment:
- Ai Arthritis
- Chronic Disease Coalition
- Committee to Protect Health Care
- Community Access National Network
- Karoll Cortez, MD- GBMC
- Amit “Mickey" Dhir, HIV Specialist
- Dr. Paul Eder
- Gilead
- HIV + HEP Policy Institute
- Infectious Disease Care Center
- Maryland Citizens Health Initiative, Maryland HealthCare for All Coalition
- Maryland Commission on LGBTQIA+ Affair
- Anya Mitchell
- Park West Health System
- Sanofi
- Sinai Hospital of Baltimore
-
Comment Received after Deadline: Dr. Catanzaro
-
Global Coalition on Aging
-
HealthHIV
January 29, 2024
The Maryland Prescription Drug Affordability Board invites you to attend the January Board Meeting, scheduled for Monday, January 29, 2024, at 2:00 pm, remotely. Part of the meeting may be conducted in closed session. Please register for the meeting here. After registering, you will receive a confirmation email with information about joining the webinar. PDAB staff politely requests that you mute your line after entering the meeting
PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email comments.pdab@maryland.gov no later than the close of business on Wednesday, January 24, 2024, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail
WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to comments.pdab@maryland.gov. Please submit any written comments concerning this agenda no later than the close of business on Wednesday, January 24, 2024.
AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.
Written Comments:
